Cerity Partners’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.1M | Buy |
76,644
+8,278
| +12% | +$1.53M | 0.02% | 554 |
|
|
2025
Q4 | $12M | Sell |
68,366
-13,882
| -17% | -$2.27M | 0.02% | 570 |
|
|
2025
Q3 | $11.5M | Buy |
82,248
+35,696
| +77% | +$4.83M | 0.02% | 529 |
|
|
2025
Q2 | $5.85M | Buy |
46,552
+6,184
| +15% | +$771K | 0.01% | 741 |
|
|
2025
Q1 | $5.52M | Buy |
40,368
+18,277
| +83% | +$2.61M | 0.01% | 702 |
|
|
2024
Q4 | $3.52M | Buy |
22,091
+14,306
| +184% | +$2.41M | 0.01% | 850 |
|
|
2024
Q3 | $1.51M | Buy |
7,785
+2,030
| +35% | +$425K | ﹤0.01% | 1214 |
|
|
2024
Q2 | $1.33M | Sell |
5,755
-631
| -10% | -$137K | ﹤0.01% | 1100 |
|
|
2024
Q1 | $1.38M | Buy |
6,386
+3,708
| +138% | +$868K | ﹤0.01% | 1134 |
|
|
2023
Q4 | $693K | Buy |
2,678
+360
| +16% | +$88.4K | ﹤0.01% | 1127 |
|
|
2023
Q3 | $596K | Sell |
2,318
-768
| -25% | -$205K | ﹤0.01% | 916 |
|
|
2023
Q2 | $879K | Buy |
3,086
+1,344
| +77% | +$400K | ﹤0.01% | 966 |
|
|
2023
Q1 | $1.32M | Sell |
1,742
-227
| -12% | -$62.8K | ﹤0.01% | 866 |
|
|
2022
Q4 | $545K | Buy |
1,969
+386
| +24% | +$109K | ﹤0.01% | 904 |
|
|
2022
Q3 | $422K | Buy |
1,583
+82
| +5% | +$17.4K | 0.01% | 776 |
|
|
2022
Q2 | $305K | Buy |
+1,501
| New | +$307K | ﹤0.01% | 902 |
|
|
2022
Q1 | – | Sell |
-860
| Closed | -$208K | – | 950 |
|
|
2021
Q4 | $208K | Buy |
+860
| New | +$221K | ﹤0.01% | 919 |
|
|
2021
Q1 | – | Sell |
-1,129
| Closed | -$277K | – | 700 |
|
|
2020
Q4 | $277K | Sell |
1,129
-1,574
| -58% | -$406K | 0.01% | 540 |
|
|
2020
Q3 | $767K | Sell |
2,703
-70
| -3% | -$19.5K | 0.03% | 271 |
|
|
2020
Q2 | $742K | Buy |
2,773
+374
| +16% | +$112K | 0.04% | 235 |
|
|
2020
Q1 | $759K | Sell |
2,399
-167
| -7% | -$50.7K | 0.05% | 243 |
|
|
2019
Q4 | $761K | Buy |
+2,566
| New | +$712K | 0.04% | 277 |
|
|
2019
Q2 | – | Sell |
-1,502
| Closed | -$355K | – | 493 |
|
|
2019
Q1 | $355K | Sell |
1,502
-648
| -30% | -$204K | 0.02% | 384 |
|
|
2018
Q4 | $647K | Buy |
2,150
+272
| +14% | +$86.8K | 0.04% | 285 |
|
|
2018
Q3 | $664K | Sell |
1,878
-65
| -3% | -$22.4K | 0.05% | 294 |
|
|
2018
Q2 | $564K | Buy |
1,943
+769
| +66% | +$216K | 0.04% | 312 |
|
|
2018
Q1 | $321K | Sell |
1,174
-150
| -11% | -$46.6K | 0.02% | 418 |
|
|
2017
Q4 | $422K | Sell |
1,324
-103
| -7% | -$33K | 0.03% | 365 |
|
|
2017
Q3 | $447K | Sell |
1,427
-549
| -28% | -$163K | 0.03% | 341 |
|
|
2017
Q2 | $536K | Buy |
1,976
+208
| +12% | +$55K | 0.04% | 222 |
|
|
2017
Q1 | $483K | Buy |
+1,768
| New | +$500K | 0.04% | 264 |
|
Other funds holding BIIB
VCM
VPM
Cerity Partners's BIIB Position: Q1 2026 in Review
Cerity Partners increased its Biogen (BIIB) stake by 12% in Q1 2026, buying an estimated $1.53M and bringing the position to 76,644 shares worth $14.1M. The position accounts for 0.02% of the portfolio, ranked #554.
Cerity Partners first reported a position in BIIB in Q1 2017 and has held it in 31 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Cerity Partners held 76,644 shares of Biogen worth $14.1M as of Q1 2026.
- Cerity Partners bought 8,278 Biogen shares in Q1 2026, an estimated $1.53M.
- Biogen made up 0.02% of Cerity Partners's portfolio in Q1 2026, its #554 holding.
- Cerity Partners first reported a position in Biogen in Q1 2017 and has held it in 31 quarters since.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.